对比增强CT+CT小肠造影与68Ga-DOTANOC PET/CT在胃肠胰神经内分泌肿瘤中的比较
回顾性纳入56例病理证实的胃肠胰神经内分泌肿瘤患者,比较对比增强CT+CT小肠造影(CECT+CTE)与68Ga-DOTANOC PET/非增强CT的诊断性能。CECT+CTE检出原发灶69个、PET/CT检出57个;未知原发灶患者病灶敏感度分别为57.7%和71.4%,分期/再分期患者分别为73.2%和73.8%。作者认为PET/CT对高分化NET分期/再分期敏感,CECT+CTE可作为互补手段考虑。
要点
- CECT+CTE检出原发灶69个,PET/CT检出57个,CECT+CTE假阳性26个多于PET/CT的9个。
- 未知原发灶患者病灶敏感度CECT+CTE 57.7%(95%CI 39.0%-74.5%)vs PET/CT 71.4%(95%CI 52.9%-84.7%)。
- 两种方法联合可使未知原发灶患者病灶敏感度升至89.7%(95%CI 73.6%-96.4%)。
核心结论
- PET/CT是对高分化神经内分泌肿瘤分期和再分期敏感的检查方法。
- 作者认为,对摄取不确定或临床高度怀疑胃肠胰神经内分泌肿瘤的患者,应考虑CECT+CTE作为互补手段,以提高病灶检出和报告信心。
研究设计与样本
- 回顾性纳入56例病理证实的胃肠胰神经内分泌肿瘤患者,平均年龄57.8±13.3岁,男女比1.95:1。
- 23例为寻找原发灶,33例为分期/再分期;所有患者均行68Ga-DOTANOC PET/非增强CT(注射111-185 MBq后60分钟)和CECT+CTE(使用1.5-2 L等渗甘露醇溶液及1-2 mg/kg静脉对比剂)。
- 由2名盲法医师独立评估,记录病灶数目、部位及报告信心(3=高信心,2=不确定,1=低信心);参考标准由临床、生化、影像参数及既往或随访扫描 corroboration 建立。
主要发现
- CECT+CTE与PET/CT检出原发灶数分别为69个和57个。
- 未知原发灶患者病灶敏感度:CECT+CTE 57.7%(95%CI 39.0%-74.5%)vs PET/CT 71.4%(95%CI 52.9%-84.7%)。
- 分期/再分期患者病灶敏感度:CECT+CTE 73.2%(95%CI 58.1%-84.3%)vs PET/CT 73.8%(95%CI 58.9%-84.7%)。
- CECT+CTE漏诊病灶:胃肠道14个、淋巴结25个、肠系膜1个、胰腺7个;PET/CT对应漏诊数分别为14、5、3、2个。
- CECT+CTE漏诊病灶中位大小9.7 mm(IQR 7.5-31.1)vs 检出病灶17.7 mm(IQR 12.2-30.0),P=0.062;PET漏诊病灶肿瘤/背景(肝脏)SUVmax比值中位1.3(IQR 0.6-3.8)vs 检出病灶4.7(IQR 2.7-10.8)。
临床怎么用
- 作者认为,对摄取不确定或临床高度怀疑胃肠胰神经内分泌肿瘤的患者,应考虑CECT+CTE作为互补手段,以提高病灶检出和报告信心。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Increase in incidence of neuroendocrine tumors (NETs) has been attributed in part to the availability of sensitive diagnostic modalities, such as Ga-DOTA-peptide PET/CT. However, it suffers from problems such as obscurement of tracer-avid lesions by physiological gut activity and collapsed gut lumen. Contrast-enhanced CT and CT enterography (CTE) do not have these drawbacks. PURPOSE: The aim of this study was to compare the diagnostic performances of contrast-enhanced CT + CTE and the Ga-DOTA-peptide PET/noncontrast CT in GEP-NETs. METHODS: Fifty-six patients (mean age, 57.8 ± 13.3 years [male:female, 1.95:1]), with histopathologically proven gastroenteropancreatic NETs, who had undergone both Ga-DOTANOC-PET/NCCT (60 minutes, post-IV injection of 111-185 MBq) and contrast-enhanced CT (CECT) + CTE (using 1.5-2 L isotonic mannitol solution and 1-2 mg/kg of IV contrast), were retrospectively selected. Twenty-three patients had been referred for identification of primary lesions and 33 for staging/restaging. The scans were independently evaluated by 2 blinded physicians, who documented the number and site of lesions, with reporting confidence (3 = high confidence, 2 = equivocal confidence, 1 = low confidence). Reference standard was created using clinical, biochemical, and imaging parameters (ie, uptake and contrast enhancement), along with corroboration from previous or follow-up scans. Finally, PET images coregistered to the CECT + CTE were independently evaluated for any additional benefit. RESULTS: The numbers of primary lesions detected by CECT + CTE and PET/CT were 69 and 57, respectively. Lesion-wise sensitivities for patients with unknown primary in CECT + CTE and PET/CT were 57.7% (95% confidence interval [CI], 39.0%-74.5%) and 71.4% (95% CI, 52.9%-84.7%), respectively. Corresponding numbers in patients who had come for staging/restaging were 73.2% (95% CI, 58.1%-84.3%) and 73.8% (95% CI, 58.9%-84.7%). Lesions missed in CECT + CTE were gastrointestinal (n = 14), lymph nodes (n = 25), mesenteric (n = 1), and pancreatic (n = 7), whereas corresponding numbers for PET/CT were 14, 5, 3, and 2. Contrast-enhanced CT + CTE showed more false-positives (n = 26) than PET/CT (n = 9). Lesions missed by CECT + CTE were smaller than detected lesions (median, 9.7 mm [interquartile range, 7.5-31.1] vs 17.7 mm [interquartile range, 12.2-30.0]; P = 0.062), and lesions missed by PET had significantly lower tumor/background (liver) SUVmax ratio (median, 1.3 [interquartile range, 0.6-3.8] vs 4.7 [interquartile range, 2.7-10.8]). The ratio of true-positives to false-positives dropped markedly, when reporting confidence in CECT + CTE was low (4/15 [for rating 1 or 2] vs 93/11 [rating 3]). Corresponding numbers for PET/CT were (40/7 [for rating 1 or 2] vs 80/2 [rating 3]). Combination of these 2 modalities would have increased the lesion-wise sensitivities in patients with unknown primaries to 89.7% (95% CI, 73.6%-96.4%) and the confidence rating of soft tissue lesions to predominantly high (134 lesions rated 3, and 10 rated 1 or 2). CONCLUSIONS: PET/CT is a sensitive modality for staging and restaging well-differentiated NETs. Use of CECT + CTE as a complementary modality in patients with uncertain uptake or high clinical suspicion of gastroenteropancreatic NETs should be considered, as it improves the lesion detection and reporting confidence.
引用
- Sharma A, Das CJ, Makharia GK, et al. Comparison of Contrast-Enhanced CT + CT Enterography and 68Ga-DOTANOC PET/CT in Gastroenteropancreatic Neuroendocrine Tumors. Clin Nucl Med. 2020. PMID: 32657875. doi:10.1097/RLU.0000000000003188
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。